News
KTTA
0.7850
+0.63%
0.0049
Weekly Report: what happened at KTTA last week (0504-0508)?
Weekly Report · 3d ago
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
PUBT · 05/05 20:46
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
TipRanks · 05/04 23:03
Pasithea Therapeutics appoints chief medical officer
Seeking Alpha · 05/04 12:34
Pasithea Therapeutics Appoints Kartik Krishnan As CMO
NASDAQ · 05/04 11:37
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
TipRanks · 05/04 11:32
Pasithea Therapeutics names Kartik Krishnan chief medical officer
PUBT · 05/04 11:05
*Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Dow Jones · 05/04 11:03
Press Release: Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Dow Jones · 05/04 11:01
Weekly Report: what happened at KTTA last week (0427-0501)?
Weekly Report · 05/04 09:23
Weekly Report: what happened at KTTA last week (0420-0424)?
Weekly Report · 04/27 09:24
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Pasithea Therapeutics Corp (KTTA)
TipRanks · 04/20 16:40
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones · 04/20 16:37
HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target
Benzinga · 04/20 16:27
Pasithea Wins FDA Rare Pediatric Disease Status For PAS-004 To Treat Neurofibromatosis Type 1
NASDAQ · 04/20 11:56
Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
TipRanks · 04/20 11:26
Pasithea Therapeutics Wins FDA Rare Pediatric Disease Tag For NF1 Drug Affecting ~115,000 Americans
Benzinga · 04/20 11:21
PASITHEA THERAPEUTICS ANNOUNCES GRANT OF RARE PEDIATRIC DISEASE DESIGNATION (RPDD) BY FDA TO PAS-004 FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)
Reuters · 04/20 11:01
Weekly Report: what happened at KTTA last week (0413-0417)?
Weekly Report · 04/20 09:23
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
PUBT · 04/18 01:45
More
Webull provides a variety of real-time KTTA stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.